Category: Research news

Positive early findings from ProQR trial of USH2A therapy

April 3, 2020

Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a …

First clinical trial participant receives CRISPR-based therapy

March 4, 2020

An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the …

First patient receives ground-breaking treatment

March 2, 2020

In January 23-year-old Jake Ternent became the first person with an inherited sight loss condition to be treated in the UK with Luxturna (voretigene neparvovec) for Leber congenital amaurosis (LCA). …

Gene therapy shows promise in tackling X-linked RP

February 28, 2020

Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients. The treatment targets retinal degeneration …

Genetic testing: an essential topic for discussion with the IRD communtiy

February 13, 2020

As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected …

Latest update from ReNeuron stem cell trial

November 15, 2019

ReNeuron has announced an encouraging update on the progress of its Phase 1/2 trial of a stem cell-based therapy for retinitis pigmentosa, describing the most recent results as a “clear …

NICE approves first treatment on the NHS for an inherited retinal dystrophy

September 4, 2019

Today the National Institute for Health and Care Excellence (NICE) has recommended  Luxturna (voretigene neparvovec) for use in the NHS in England, making it the first available treatment for an …

ProQR Announces Clearance of IND to Start Clinical Trial

August 14, 2019

ProQR Therapeutics announced on Monday 12 August that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QR-1123, which is the first investigational medicine to …

Awaiting funding decision for Luxturna

In the last issue of Look Forward, we reported that the gene therapy Luxturna had won European regulatory approval for the treatment of a particular type of inherited sight loss. …

Southampton researchers embark on clinical trial for Stargardt disease

July 3, 2019

Researchers in Southampton are recruiting people living with Stargardt disease for the clinical trial of a new drug called Remofuscin that could limit the sight loss associated with this condition. …

Research in the news (April – June 2019)

July 1, 2019

There have been some exciting research developments from around the world in the last few weeks. Here are two stories that we have already shared via Facebook and Twitter. Calming …

‘Encouraging’ early stage results from stem cell therapy trial

April 15, 2019

‘Encouraging’ early stage results have been reported from an ongoing clinical trial for a stem cell therapy for retinitis pigmentosa. Retina UK has welcomed the news, while stressing ‘cautious optimism’ …